Ophthalmic surgical device specialist Eyecare Tech Instruments (科明儀器) is capitalizing on market tailwinds driven by demographic aging. The company's licensed femtosecond cataract surgery equipment now commands over 50% market share in Taiwan, securing its position as the market leader. Chairman Chiang Chin-hsien announced on May 19, 2026, that Eyecare Tech plans to submit its official IPO application in June, with the objective of transitioning from the Emerging Stock Board to a mainboard listing on the Taipei Exchange (TPEx) by November 2026. Management is forecasting strong H2 performance, driven by population aging and increased screen time from digital devices, which are accelerating demand for premium intraocular lenses (IOLs).

Corporate Lineage and Financial Diagnostics

Eyecare Tech is an affiliate of the renowned Clinico Group (科林集團), an enterprise with over 40 years of history that originated in ophthalmic distribution. Today, the group is widely recognized for Clinico International, which operates Taiwan’s largest audiology and hearing aid retail chain. Founded 13 years ago by Clinico Group founder Lin Wen-cheng, individual principal shareholders of Clinico still retain a 70% equity stake in Eyecare Tech Instruments.

Eyecare Tech's consolidated revenue for the first four months of 2026 stood at NT$208 million (-2.7% YoY), a temporary variance attributed entirely to deferred equipment revenue recognition timelines. Institutional analysts project that Eyecare Tech will maintain its historical 20% compound annual revenue growth rate, positioning full-year 2026 revenue to hit NT$830 million.

Clinical Footprint and Portfolio Expansion

Out of approximately 900 ophthalmic clinics and hospitals across Taiwan, roughly 647 sites perform cataract surgeries. There are currently about 130 active femtosecond cataract surgery laser systems nationwide, with Eyecare Tech supplying over half of this installed base.

In the IOL sector, Eyecare Tech distributes for Japan's HOYA, currently holding an 11% market share (ranking third nationwide). Taiwan's self-pay IOL market comprises eight distinct categories. To capture unmet segments, Eyecare Tech is systematically expanding its product pipeline in H2 2026:

• Q3 2026: Launching into the extended depth of focus (EDOF) IOL segment.
• Q4 2026: Introducing implantable phakic contact lenses (IPCL) and home-use tonometers to capture refractive and glaucoma clinical pathways.

On the equipment front, Eyecare Tech continues to scout advanced global medical assets. It currently acts as the distributor for premier European brands, including Ziemer (Switzerland) and SCHWIND (Germany). In Q2 2026, the company will roll out the VirtuaLens Virtual Reality Simulation System, designed to assist medical institutions in optimizing self-pay patient conversion rates through immersive clinical previewing.

Demographic Drivers

Demographic projections indicate that by 2040, individuals aged 65 and older will account for 31% of Taiwan's population. Nearly 80% of individuals over 50 suffer from presbyopia, while over 60% of those above 65 present with clinical cataracts, with a notable shift toward younger demographics. This long-term demographic trend ensures a growing baseline for annual surgical volumes, benefiting Eyecare Tech's consumable and equipment portfolio.

Resource: 飛秒白內障設備龍頭科明6月申請、11月興櫃轉上櫃 全年營收拚增兩成